Immunotherapy Approaches for Urothelial Bladder Cancer: Expert Guidance Through Challenging Cases

Join us for this CME-certified satellite symposium in partnership with the Bladder Cancer Advocacy Network at ASCO GU 2018. Hear from experts on how to integrate immune checkpoint inhibitors into your oncology practice, including insights into their development, review of available clinical data, and current approvals for patients with bladder cancer.

Sign up now! Registration is complimentary.

Not an official event of the 2018 Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

Agenda

6:30 PM - 7:00 PM Dinner and Registration
7:00 PM - 7:10 PM Welcome and Introduction
7:10 PM - 7:20 PM History and Development of Immunotherapy in Bladder Cancer
7:20 PM - 8:50 PM Case Discussions

  • Neoadjuvant and adjuvant immunotherapy approaches
  • Optimal use of immune checkpoint inhibitors for first-line therapy in advanced disease
  • Immune checkpoint inhibitors after progression on platinum-based chemotherapy
  • Administration considerations and immune-related adverse event management
  • Options for treatment after discontinuing immune checkpoint inhibitors

Faculty Panel Discussion and Audience Questions
For each case presented, faculty will lead a discussion on available clinical data that could guide the treatment choice for the case.

8:50 PM - 9:00 PM Final Thoughts and Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Chair
Elizabeth Plimack, MD

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Faculty
Andrea Apolo, MD

Genitourinary Malignancies Branch
Head, Bladder Cancer Section
NIH Lasker Clinical Research Scholar
National Cancer Institute Center for Cancer Research
Bethesda, Maryland

Faculty
Jean Hoffman-Censits, MD

Associate Professor
Department of Medical Oncology
Sidney Kimmel Cancer Center at Jefferson
Philadelphia, Pennsylvania

Faculty
Matthew I. Milowsky, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

CME

Goal Statement
The goal of this activity is to improve participants’ competence and performance in using immune checkpoint inhibitors to improve outcomes for patients with locally advanced or metastatic urothelial carcinoma.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with urothelial bladder cancer.

Learning Objectives

  • Gain insight on the mechanism of action and rationale for using immune checkpoint inhibitors to treat patients with advanced urothelial carcinoma
  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, considering the available evidence, patient and disease characteristics, as well as patient preferences
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors
  • Evaluate the benefits of monotherapy and combination checkpoint inhibitor therapies as part of first-line, second-line, and subsequent lines of therapy for advanced urothelial carcinoma

Accreditation

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, Clinical Care Options, LLC and the Bladder Cancer Advocacy Network. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.